VZL 2009, 78(4):150-153

Sibutramine and Health-Related Quality of Life: Findings of Prospective, Longitudinal Study

Ladislav Slováček1, Vladimír Pavlík ORCID...2
1 University of Defence, Faculty of Military Health Sciences, Department of Field Internal Medicine, Hradec Králové, Czech Republic
2 University of Defence, Faculty of Military Health Sciences, Department of Hygiene, Hradec Králové, Czech Republic

Základní informace: Obezita je multifaktoriální chronická porucha, jež dosáhla epidemických rozměrů ve většině vyspělých zemí a je nebezpečí, že se stane celosvětovou epidemií.

Cíle: Studie hodnotí vliv sibutraminové terapie na zdraví a kvalitu života u obézních pacientů.

Pacienti a metody: Studie je místní perspektivní a dlouhodobá. Vedena byla v České republice na katedře hygieny Fakulty vojenského zdravotnictví v Hradci Králové. Data byla získávána v průběhu roku 2007. Dvacet dva obézních pacientů (6 mužů a 16 žen) bylo léčeno sibutraminem v dávkování 10 mg/den. Všech 22 pacientů bylo starších 18 let. Pro hodnocení zdraví a kvality života pacientů byl použit evropský dotazník Quality of Life Questionnaire - verze EQ-5D.

Výsledky: Statistické vyhodnocení ukazuje, že zdraví a kvalita života (EQ-5D skóre a EQ-5D vizuální analogová škála) vykazuje vysoce významnou statistickou závislost na sibutraminové terapii (p < 0.05).

Závěr: Výsledky ukázaly, že sibutraminová terapie má vysoce pozitivní vliv na zdraví a kvalitu života obézních pacientů.

Keywords: Sibutramin; Zdraví a kvalita života; Obézní pacienti

Background: Obesity is a multifactorial, chronic disorder that has reached epidemic proportions in most industrialized countries and is threatening to become a global epidemic.

Aims: The study evaluates the effect of sibutramine therapy on health-related quality of life of obese patients.

Patients and Methods: The study is local, prospective and longitudinal. It was carried out at Department of Hygiene of Faculty of Military Health Sciences in Hradec Králové, Czech Republic. Data were obtained during the year 2007. Twenty-two obese patients (6 males and 16 females) were treated by sibutramine in dose of 10 mg/day. All of these 22 patients were aged over 18 years. The European Quality of Life Questionnaire - EQ-5D Version was applied for evaluation of health-related quality of life among obese patients.

Results: The statistical evaluation demonstrates that health-related quality of life (EQ-5D score and EQ-5D visual analogue scale) presents highly significant statistical dependence on sibutramine therapy (p < 0.05).

Conclusion: The results showed that sibutramine therapy has a highly positive effect on health-related quality of life of obese patients.

Keywords: Sibutramine; Health-related quality of life; Obese patients

Received: March 3, 2009; Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slováček, L., & Pavlík, V. (2009). Sibutramine and Health-Related Quality of Life: Findings of Prospective, Longitudinal Study. Vojenské Zdravotnické Listy, 78(4), 150-153
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Di FRANCESCO, V. - SACCO, T. - ZAMBONI, M., et al. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. Ann. Nutr. Metab., 2007; vol. 51, p. 75-81. Go to original source... Go to PubMed...
    2. LUQUE, CA. - REY, JA. The discovery and status of sibutramine as an anti-obesity drug. Eur. J. Pharmacol., 2002, vol. 440, p. 119-128. Go to original source... Go to PubMed...
    3. NISOLI, E. - CARRUBA, MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf., 2003, vol. 26, p. 1024-1048. Go to original source... Go to PubMed...
    4. PAYER, J. - HAINER, V. - ONDREJKA, P., et al. Sibutramine in obesity treatment (multicenter, open, prospective 12-month-long study. Vnitř. Lék., 2004, vol. 50, p. 825-829.
    5. SLOVÁČEK, L. - BOHUTÍNSKÁ, H. - KAŠLÍKOVÁ, M., et al. Occurence of depression symptoms in peripheral arterial occlusive disease. Voj. zdrav. Listy, 2008, roč. 77, s. 29-32.
    6. SLOVACEK, L. - SLOVACKOVA, B. - CHOVANEC, V. The efect of femoral and popliteal percutaneous transluminal balloon angioplasty on patients quality of life. Sao Paulo Med. J., 2007, vol. 125, p. 250-252. Go to original source... Go to PubMed...
    7. SLOVACEK, L. - SLOVACKOVA, B. - JEBAVY, L. Global Quality of Life in Patients Who Have Undergone the Hematopoietic Stem Cell Transplantation: Finding from Transversal and Retrospective Study. Exp. Oncol., 2005, vol. 27, p. 238-242. Go to PubMed...
    8. THE EUROQol GROUP. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy, 1990, vol. 16, p. 199-208. Go to original source... Go to PubMed...
    9. WARREN, E. - BRENNAN, A. - AKEHURST, R. Cost-effectiveness of sibutramine in the treatment of obesity. Med. Decis. Making, 2004, vol. 24, p. 9-19. Go to original source... Go to PubMed...
    10. WIRTH, A. Weight loss via drug therapy. Internist (Berl)., 2003, vol. 44, p. 359-366. Go to original source... Go to PubMed...

    Return to the content